Reducing hospitalization in elderly influenza vaccine recipients
View Patent ↗Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
1. An immunization method comprising:
administering at least one adjuvanted vaccine chosen from an adjuvanted influenza A virus seasonal vaccine and an adjuvanted influenza B virus seasonal vaccine to each member of a predetermined community of elderly human subjects in consecutive influenza seasons, wherein the vaccine is administered to each recipient in an amount sufficient to inhibit at least one condition chosen from pneumonia and influenza in the recipient and thereby reduce the recipient's incidence of hospitalization for the condition during the peak of each of the influenza seasons relative to a population of human subjects which receives an unadjuvanted influenza vaccine;
wherein each recipient of the adjuvanted vaccine and each recipient of the unadjuvanted vaccine is at least 65 years old;
further wherein none of the recipients of the adjuvanted influenza vaccine receives an unadjuvanted influenza vaccine during any of the influenza seasons;
and further wherein the adjuvanted and unadjuvanted influenza vaccines are split virus antigen vaccines.
2. The method of claim 1 , wherein the adjuvanted and unadjuvanted influenza vaccines have the same dosage volume, amount of antigen, virus strains, antigen type and non-adjuvant excipients.
3. The method of claim 2 , wherein the adjuvanted vaccine comprises the unadjuvanted vaccine and an adjuvant.
4. The method of claim 1 , wherein the adjuvanted and unadjuvanted influenza vaccines are administered intramuscularly.
5. The method of claim 1 , wherein the influenza vaccine is adjuvanted with an oil-in-water emulsion.
6. The method of claim 5 , wherein the emulsion comprises squalene.
7. The method of claim 6 , wherein the emulsion comprises squalene, polysorbate 80, and sorbitan trioleate.
8. The method of claim 6 , wherein the emulsion comprises squalene, an α-tocopherol, and polysorbate 80.
9. The method of claim 6 , wherein the emulsion comprises squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant and a hydrophobic nonionic surfactant.
10. The method of claim 6 , wherein the emulsion comprises squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate.
11. The method of claim 5 , wherein the emulsion has oil droplets with a size less than 220 nm.
12. The method of claim 8 , wherein the emulsion has oil droplets with an average diameter of between 100 and 250 nm.
13. The method of claim 9 , wherein at least 90% of the oil droplets (by volume) in the emulsion have a size less than 200 nm.
14. An immunization method comprising:
intramuscularly administering at least one adjuvanted tetravalent vaccine chosen from an inactivated, adjuvanted tetravalent influenza A virus seasonal vaccine and an inactivated, adjuvanted tetravalent influenza B virus seasonal vaccine to each member of a predetermined community of elderly human subjects in each of two consecutive influenza seasons, wherein the vaccine is administered to each recipient in an amount sufficient to inhibit at least one condition chosen from pneumonia and influenza in the recipient and thereby reduce the recipient's incidence of hospitalization for the condition during the peak of each of the influenza seasons relative to a population of human subjects which receives the influenza vaccine in unadjuvanted form;
wherein the adjuvanted vaccine is a purified surface antigen vaccine and the adjuvant is an oil-in-water submicron emulsion comprising squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate;
further wherein each recipient of the adjuvanted vaccine and each recipient of the unadjuvanted vaccine is at least 65 years old;
and further wherein none of the recipients of the adjuvanted influenza vaccine receives an unadjuvanted influenza vaccine in any of the two consecutive influenza seasons.
15. The method of claim 14 , wherein the adjuvanted and unadjuvanted influenza vaccines have the same dosage volume, amount of antigen, virus strains, antigen type and non-adjuvant excipients.
16. The method of claim 15 , wherein the adjuvanted vaccine comprises the unadjuvanted vaccine and an adjuvant.
17. The method of claim 14 , wherein the emulsion has oil droplets with a size less than 220 nm.
18. An immunization method comprising:
intramuscularly administering at least one adjuvanted vaccine chosen from a trivalent or tetravalent, inactivated, adjuvanted influenza A virus seasonal vaccine and a trivalent or tetravalent, inactivated, adjuvanted influenza B virus seasonal vaccine to each member of a predetermined community of elderly human subjects in each of three consecutive influenza seasons, wherein the vaccine is administered to each recipient in an amount sufficient to inhibit at least one condition chosen from pneumonia and influenza in the recipient and thereby reduce the recipient's incidence of hospitalization for the condition during the peak of each of the influenza seasons relative to a population of human subjects which receives the influenza vaccine in unadjuvanted form;
wherein the adjuvanted vaccine is a purified surface antigen vaccine and the adjuvant is an oil-in-water submicron emulsion comprising squalene, polyoxyethylene sorbitan monooleate, sorbitan trioleate, and oil droplets with a size less than 220 nm;
further wherein each recipient of the adjuvanted vaccine and each recipient of the unadjuvanted vaccine is at least 65 years old and was not a resident of a hospital, nursing home, or rehabilitation center or received home care in the 30 days preceding immunization;
and further wherein none of the recipients of the adjuvanted influenza vaccine receives an unadjuvanted influenza vaccine in any of the three consecutive influenza seasons.
19. The method of claim 18 , wherein the adjuvanted and unadjuvanted influenza vaccines have the same dosage volume, amount of antigen, virus strains, antigen type and non-adjuvant excipients.
20. The method of claim 19 , wherein the adjuvanted vaccine comprises the unadjuvanted vaccine and an adjuvant.
21. The method of claim 18 , wherein the adjuvanted vaccine is a trivalent vaccine.
22. The method of claim 18 , wherein the adjuvanted vaccine is a tetravalent vaccine.